Article
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Antiviral therapy - 1 Jan 2015
Akil Bisher, Blick Gary, Hagins Debbie P, Ramgopal Moti N, Richmond Gary J, Samuel Rafik M, Givens Naomi, Vavro Cindy, Song Ivy H, Wynne Brian, Ait-Khaled Mounir
Abstract excerpt
BACKGROUND: The Phase III VIKING-3 study demonstrated that dolutegravir (DTG) 50 mg twice daily was efficacious in antiretroviral therapy (ART)-experienced subjects harbouring raltegravir- and/or elvitegravir-resistant HIV-1. VIKING-4 (ING116529) included a placebo-controlled 7-day monotherapy phase to demonstrate that short-term antiviral activity was attributable to DTG. METHODS: VIKING-4 is a Phase III...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.